Patrick Schöffski

TL;DR: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivoliumab alone than in those who received ipil optimumab alone, with no apparent loss of quality of life in the patients whoreceived regimens containing nivolinumab.

TL;DR: In this article, a randomized, double-blind, placebo-controlled study was conducted to determine whether the addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) to standard gemcitabine therapy improves overall survival in advanced pancreatic cancer.

TL;DR: Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patientswith leiomyosarcoma, synovial sarcomas, and other STS types.

TL;DR: In a broad population of patients with metastatic RCC, the safety profile of sunitinib 50 mg once-daily (initial dose) on schedule 4-2 was manageable and efficacy results were encouraging, particularly in subgroups associated with poor prognosis who are not usually entered into clinical trials.

TL;DR: XELOX provides a more convenient regimen, likely to be preferred by both patients and healthcare providers, and has the potential to replace FU/LV in combination with oxaliplatin for MCRC.